近日 ，深圳科思明德医疗科技有限公司 （以下简称"科思明德"）宣布完成 数亿元人民币A+轮融资 。本轮融资由知名产业机构领投，雅惠投资跟投，老股东IDG资 本持续加码。熙桥资本作为独家财务顾问，助力此次融资顺利推进。所筹资金将主要用于 软式内窥镜系列产品的品牌建设和国内外商业投入，以及加速多管线研发 进程 。 # 关于科思明德 科思明德 成立于2022年9月9日，总部位于深圳市龙华区。公司专注于消化科软式电子内窥镜产品的研发与生产，致力于挖掘临床需求，精细打造优质产品，为临 床用户提供最佳的诊断及治疗解决方案。 科思明德团队汇集了来自国际和国内龙头医疗科技公司和一流大学的人才，具备丰富的产品研发及生产经验。公司核心团队深度参与并推动了 首台国产高清内镜 以及 首套国产超声内镜 的研发、量产与全球营销。 科思明德的一体化软镜技术平台已覆 盖全国近千家医院 ，包括头部教学三甲医院及县域市场等不同级别医院。此外，公司也在积极布局海外市场。 融资历程 思宇年度活动回顾： 首届全球眼科大会 | 首届全球骨科大会 | 首届全球心血管大会 | 首届全球医美科技大会 即将召开： 2025年7月17日，第二届全球医疗科技大会 ...

Group 1 - The core viewpoint emphasizes the importance of controlling the progression of myopia in children rather than attempting to reverse it, as most optical methods can only slow down the increase in myopia [2][3] - For children around the age of 10 with myopia under 100 degrees, optical methods like functional frame glasses and OK lenses may show some cases of myopia regression, but this is not common [2] - It is crucial to conduct cycloplegic refraction tests to accurately assess myopia, as traditional vision tests may not detect low degrees of myopia in children who still have normal visual acuity [3] Group 2 - For children who have already developed myopia, intervention measures should be tailored based on the degree of myopia and astigmatism, as well as the individual child's situation [3] - Functional frame glasses or OK lenses are recommended for children with relatively low myopia and high astigmatism, but adjustments should be made based on the child's response and axial growth [3] - Children with low myopia or pure astigmatism may be better suited to wear frame glasses [3]

Core Viewpoint - The company reported strong revenue growth in 2024, but faced a decline in net profit in Q1 2025 due to market pressures from centralized procurement and reduced surgical volumes [1][2]. Financial Performance - In 2024, the company achieved revenue of 1.41 billion yuan, a year-on-year increase of 48.24%, and a net profit of 388 million yuan, up 27.77% [1]. - For Q1 2025, revenue was 357 million yuan, reflecting a year-on-year growth of 15.07%, while net profit decreased to 93 million yuan, down 10.05% [1]. Product Performance - Revenue from artificial crystalline lenses reached 588 million yuan in 2024, growing by 17.66%, with sales volume increasing by 44.93% [2]. - The company’s revenue from myopia control products grew by 20.79%, driven by the introduction of various new products [2]. R&D Investment and New Business Growth - The company increased R&D investment to 160 million yuan in 2024, a rise of 20.80%, representing 11.33% of total revenue [3]. - The contact lens business saw significant growth, with revenue reaching 426 million yuan, a staggering increase of 211.84% [3]. Market Outlook - The company is projected to achieve revenues of 1.81 billion yuan, 2.26 billion yuan, and 2.79 billion yuan for 2025-2027, with respective growth rates of 28.44%, 24.91%, and 23.12% [4]. - Expected net profits for the same period are 467 million yuan, 600 million yuan, and 778 million yuan, with growth rates of 20.21%, 28.55%, and 29.63% [4]. Earnings Per Share - The projected EPS for the years 2025, 2026, and 2027 are 2.46 yuan, 3.17 yuan, and 4.10 yuan respectively [5].